AviadoBio Secures $72M in Series B Funding to Accelerate Breakthrough Gene Therapy for FTD and ALS

AviadoBio is proud to announce a successful funding round that raised an impressive $72,000,000, marking a significant milestone in our mission to revolutionize treatments for neurodegenerative diseases. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for those living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This newly secured capital will empower our innovative work in gene therapy and precision delivery systems, allowing us to further develop and scale our proprietary platforms designed to overcome the formidable challenges of delivering the right treatment to the right location within the brain. Our approach is firmly rooted in neuroanatomy-led research, an initiative born from pioneering studies at King’s College London and the UK Dementia Research Institute, which enables us to maximize the therapeutic potential of revolutionary gene therapies. The infusion of funds not only underscores the confidence that investors place in our strategic vision but also accelerates our pipeline of novel therapies aimed at halting, and potentially reversing, the progression of debilitating neurodegenerative conditions. In the coming months, this funding will support advanced clinical research, expand our state-of-the-art manufacturing capabilities, and drive further collaboration with leading scientific and clinical experts. As we embark on this exciting chapter, AviadoBio is more committed than ever to transforming our deep understanding of the brain into meaningful, transformative treatments, offering hope to patients and families affected by FTD and ALS worldwide.